X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SPOR COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. It is being developed for for COVID-19 and Influenza.
Lead Product(s): Bacillus Bacteria
Therapeutic Area: Infections and Infectious Diseases Product Name: SPOR-COV
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: SporeGen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Under the terms of the deal, Sebela will lead the future clinical development and commercialisation activities of NTCD-M3 in North America. NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins.
Lead Product(s): NTCD-M3
Therapeutic Area: Infections and Infectious Diseases Product Name: NTCD-M3
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sebela Pharmaceuticals
Deal Size: $570.0 million Upfront Cash: $1.0 million
Deal Type: Collaboration February 24, 2023
Details:
The net proceeds of the Fundraising will allow the Company to complete final Phase 3 clinical trial preparation for NTCD-M3, Destiny pharma’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence.
Lead Product(s): NTCD-M3
Therapeutic Area: Infections and Infectious Diseases Product Name: NTCD-M3
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: finnCap Limited
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Financing February 24, 2023
Details:
XF-73 reduced the mean nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery in the micro-ITT (Intend to Treat) population, a statistically highly significant result.
Lead Product(s): Exeporfinium chloride
Therapeutic Area: Infections and Infectious Diseases Product Name: XF-73
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
XF-73 is a first-in-class drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of postsurgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus.
Lead Product(s): Exeporfinium chloride
Therapeutic Area: Infections and Infectious Diseases Product Name: XF-73
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
Destiny Pharma reported that it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the prevention of C. difficile infection (CDI) recurrence.
Lead Product(s): NTCD-M3
Therapeutic Area: Infections and Infectious Diseases Product Name: NTCD-M3
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.
Lead Product(s): SPOR-COV
Therapeutic Area: Infections and Infectious Diseases Product Name: SPOR-COV
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: SporeGen
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2020
Details:
Positive interim safety review has been completed by an Independent Data Monitoring Committee (IDMC) of the Company’s ongoing Phase 2b study of its lead asset XF-73 in the prevention of post-surgical bacterial infections.
Lead Product(s): Exeporfinium chloride
Therapeutic Area: Infections and Infectious Diseases Product Name: XF-73
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
Destiny Pharma agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value. The study is evaluating XF-73 for the prevention of post-surgical hospital infections caused by Staphylococcus aureus bacteria, such as MRSA.
Lead Product(s): Exeporfinium chloride
Therapeutic Area: Infections and Infectious Diseases Product Name: XF-73
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
Data published to date support the unique target profile of XF-73 and its potential to address the threat of AMR.
Lead Product(s): Exeporfinium chloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
